A systematic review of cost-effective analyses of pembrolizumab for several indications

Quist, S. (2019) A systematic review of cost-effective analyses of pembrolizumab for several indications. Bachelor's Thesis, Pharmacy.

Preview	Text bPHAR_2019_QuistSW.pdf Download (442kB) | Preview
	Text toestemming.pdf Restricted to Registered users only Download (120kB)

Abstract

Pembrolizumab is a promising immune checkpoint inhibitor engaging on the Programmed-Death-1(PD-1)-receptor. [1,2,3,4] A problem with pembrolizumab is the potential high budget impact. [5] In this review different cost-effective analyses are reviewed. Materials and Methods: During this review a systematic search on PubMed is done and ‘pembrolizumab’ and ‘cost effectiveness’ are used as search terms. In a qualitative analysis the relevant articles will be studied on several key points. Results: The PubMed search delivered 33 hits. Also, two articles were found by snowballing. 17 records were excluded, and 7 full-text articles were excluded. Resulting in 11 articles remaining for the qualitative analysis. Pembrolizumab was only found cost-effective for non-small-lung-cell-cancer in US perspectives. Pembrolizumab was found cost-effective for melanoma in all articles and not found costeffective for bladder cancer in any of the articles. One article studying Hodgkin’s lymphoma was reviewed, which established pembrolizumab as cost-effective. Conclusion: The cost-effectiveness of pembrolizumab is very different for different countries and indications. The overall conclusions in countries are similar but there is a lot of difference in exact outcomes for the same countries and indications due to difference in setups of the cost-effectiveness analyses.

Item Type:	Thesis (Bachelor's Thesis)
Supervisor name:	Postma, M.J.
Degree programme:	Pharmacy
Thesis type:	Bachelor's Thesis
Language:	English
Date Deposited:	10 May 2019
Last Modified:	14 May 2019 09:24
URI:	https://fse.studenttheses.ub.rug.nl/id/eprint/19455

Actions (login required)

View Item